Literature DB >> 10362524

A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.

K C Chou1, K D Watenpaugh, R L Heinrikson.   

Abstract

Tau protein kinase II (TPKII) is a heterodimer comprising a catalytic cyclin-dependent kinase subunit (Cdk5) and a regulatory protein called neuronal Cdk5 activator (Nck5a). TPKII is somewhat reminiscent, therefore, of the Cdk2-cyclin complex important in cell cycle regulation. In fact, although the amino acid sequence of Nck5a has little similarity to those of cyclins, recent experimental results obtained by site-directed mutagenesis studies have indicated that its activation domain, Nck5a*, may adopt a conformation of the cyclin-fold structure. Based on this structural inference, a 3-dimensional model of the Cdk5-Nck5a*-ATP complex was derived from the X-ray structure of Cdk2-cyclinA-ATP complex. The computed structure for TPKII is fully compatible with experimental data derived from studies of the Cdk5-Nck5a system, and also predicts which amino acid residues might be involved in formation of the Cdk5-Nck5a* interface and ATP binding pocket in TPKII. The computational structure also shows the interactive region of Nck5a* and the T-loop of Cdk5, a critical region in TPKII which functions as a gate-control-lever of the catalytic cleft. Furthermore, a physical mechanism is put forth to explain why the activation of TPKII is not dependent upon phosphorylation of the Cdk5 subunit, a puzzle long-standing in this area. These findings provide a model with which to consider design of compounds which might serve as inhibitors of TPKII. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362524     DOI: 10.1006/bbrc.1999.0792

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  Modelling the molecular mechanism of protein-protein interactions and their inhibition: CypD-p53 case study.

Authors:  S M Fayaz; G K Rajanikant
Journal:  Mol Divers       Date:  2015-07-14       Impact factor: 2.943

2.  Docking and molecular dynamics study on the inhibitory activity of N, N-disubstituted-trifluoro-3-amino-2-propanols-based inhibitors of cholesteryl ester transfer protein.

Authors:  Bo-Liang Dong; Qing-Hua Liao; Jing Wei
Journal:  J Mol Model       Date:  2010-11-06       Impact factor: 1.810

3.  CDK5 activator protein p25 preferentially binds and activates GSK3β.

Authors:  Hei-Man Chow; Dong Guo; Jie-Chao Zhou; Guan-Yun Zhang; Hui-Fang Li; Karl Herrup; Jie Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

4.  Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies.

Authors:  Rajesh B Patil; Euzebio G Barbosa; Jaiprakash N Sangshetti; Vishal P Zambre; Sanjay D Sawant
Journal:  Mol Divers       Date:  2018-03-13       Impact factor: 2.943

5.  New insight into poly (3-hydroxybutyrate) production by Azomonas macrocytogenes isolate KC685000: large scale production, kinetic modeling, recovery and characterization.

Authors:  Noha S Elsayed; Khaled M Aboshanab; Mahmoud A Yassien; Nadia H Hassouna
Journal:  Mol Biol Rep       Date:  2019-04-17       Impact factor: 2.316

6.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943

Review 7.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

8.  Modular prediction of protein structural classes from sequences of twilight-zone identity with predicting sequences.

Authors:  Marcin J Mizianty; Lukasz Kurgan
Journal:  BMC Bioinformatics       Date:  2009-12-13       Impact factor: 3.169

9.  Structural origins for the loss of catalytic activities of bifunctional human LTA4H revealed through molecular dynamics simulations.

Authors:  Sundarapandian Thangapandian; Shalini John; Prettina Lazar; Sun Choi; Keun Woo Lee
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.

Authors:  Lei Liu; Ying Ma; Run-Ling Wang; Wei-Ren Xu; Shu-Qing Wang; Kuo-Chen Chou
Journal:  Drug Des Devel Ther       Date:  2013-04-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.